ILM1 Stock Chart & Stats
CHF11.71
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF11.71
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF11.23 - CHF11.83
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
CHF262.91M
Enterprise ValueCHF404.01
Total Cash (Recent Filing)CHF92.85M
Total Debt (Recent Filing)CHF202.69M
Price to Earnings (P/E)22.3
Beta0.24
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)0.71
Price to Sales (P/S)0.17
P/FCF Ratio9.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF19.61Price Target Upside67.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.24
Revenue Forecast (FY)CHF1.97B
Bulls Say, Bears Say
Bulls Say
Specialized Business ModelMedios’ focus on patient-individual therapies and specialty pharma distribution creates durable niche positioning with higher switching costs and specialized service needs. This structural specialization supports recurring, mission-critical demand from pharmacies and healthcare providers over months.
Scale And Steady RevenueA multibillion-euro revenue base gives Medios buying scale and distribution leverage versus smaller competitors. Modest but consistent revenue growth reflects resilient end-market demand, supporting fixed-cost absorption and long-term supplier/customer relationships.
Positive Free Cash Flow And Improving Operating MarginSustained positive FCF and rising EBITDA margin indicate improving operational efficiency and internal funding capacity. This durability enables reinvestment, working-capital management or selective deleveraging even if margins remain structurally thin.
Bears Say
Structurally Thin MarginsVery low gross and net margins limit the firm's buffer against cost inflation, reimbursement pressure, or supply shocks. Thin profitability compresses retained earnings and constrains ability to invest organically or build reserves, raising long-term earnings vulnerability.
Low Returns On CapitalA ~3% ROE signals weak capital efficiency versus peers; low returns reduce the firm's ability to compound shareholder value and increase reliance on operational improvements or external financing to drive meaningful long-term growth.
Higher Debt And Uneven Cash ConversionRising debt levels increase sensitivity to interest rates and earnings volatility given small OCF relative to scale. Coupled with uneven cash conversion, this weakens financial flexibility and heightens refinancing and working-capital risks over the medium term.
Medios AG News
ILM1 FAQ
What was Medios AG’s price range in the past 12 months?
Medios AG lowest stock price was CHF11.23 and its highest was CHF11.83 in the past 12 months.
What is Medios AG’s market cap?
Medios AG’s market cap is CHF262.91M.
When is Medios AG’s upcoming earnings report date?
Medios AG’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.
How were Medios AG’s earnings last quarter?
Medios AG released its earnings results on May 12, 2026. The company reported CHF0.409 earnings per share for the quarter, beating the consensus estimate of CHF0.204 by CHF0.204.
Is Medios AG overvalued?
According to Wall Street analysts Medios AG’s price is currently Undervalued.
Does Medios AG pay dividends?
Medios AG does not currently pay dividends.
What is Medios AG’s EPS estimate?
Medios AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medios AG have?
Currently, no data Available
What happened to Medios AG’s price movement after its last earnings report?
Medios AG reported an EPS of CHF0.409 in its last earnings report, beating expectations of CHF0.204. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Medios AG?
Currently, no hedge funds are holding shares in CH:ILM1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medios AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF19.61 (67.42% Upside)
CHF19.61 (67.42% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.41%
Trailing 12-Months
Company Description
Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.
ILM1 Company Deck
ILM1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance and strategic advancements, despite some challenges in specific segments and increased costs related to acquisitions.View all CH:ILM1 earnings summariesILM1 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
CHF19.61
▲(67.42% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
MATERNUS-Kliniken AG
―
Limes Schlosskliniken AG
―
Eifelhoehen-Klinik AG
―
Gesundheitswelt Chiemgau AG
―
M1 Kliniken AG
―






